Tusk Therapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $764M
Latest Deal Amount

Tusk Therapeutics General Information

Description

Developer of an innate immune system designed to harness the power of the immune system for the treatment of cancer. The company's system is developing novel immune modulating therapeutics based on an in-depth understanding of the innate immune system with a special focus on Natural Killer (NK) cell biology, enabling cancer patients to get full recovery.

Contact Information

Website
www.tusktherapeutics.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Therapeutic Devices
Acquirer
Roche Holding
Primary Office
  • Stevenage Bioscience Catalyst
  • Gunnels Wood Road, Stevenage
  • Hertfordshire SG1 2FX
  • England, United Kingdom
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Tusk Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 01-Oct-2018 $764M 00000 Completed Pre-Clinical Trials
3. Grant 14-Nov-2017 00.000 Completed Pre-Clinical Trials
2. Early Stage VC Completed Startup
1. Accelerator/Incubator Completed Startup
To view Tusk Therapeutics’s complete valuation and funding history, request access »

Tusk Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of an innate immune system designed to harness the power of the immune system for the treatment of cancer. The
Biotechnology
Hertfordshire, United Kingdom
0000 0000-00-00
000000&0

00000000

ua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
0000000000000
Gaithersburg, MD
00 As of 0000
000.00
00000000 000.00

0000 000

didunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco
0000000000000
Santa Monica, CA
000 As of 0000
00000
000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tusk Therapeutics Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Venture Capital-Backed Gaithersburg, MD 00 000.00 00000000 000.00
0000 000000 Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
000000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000 00000
00000 000000000000 Corporate Backed or Acquired Cambridge, United Kingdom 000 00000 000000&0 00000
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
You’re viewing 5 of 30 competitors. Get the full list »

Tusk Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Matthew Hall Chief Financial Officer
Kevin Moulder Ph.D Chief Development Officer
Pascal Merchiers Ph.D Vice President of Research & Development
Dominic Smethurst Chief Medical Officer
To view Tusk Therapeutics’s complete executive team members history, request access »

Tusk Therapeutics Board Members (6)

Name Representing Role Since
Eric Rowinsky Tusk Therapeutics Board Member 000 0000
George Golumbeski Ph.D Tusk Therapeutics Board Member 000 0000
Terry Rosen Tusk Therapeutics Board Member 000 0000
You’re viewing 3 of 6 board members. Get the full list »

Tusk Therapeutics Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Droia Oncology Ventures Venture Capital Minority 000 0000 000000 0
Innovate UK Government 000 0000 000000 0
Stevenage Bioscience Catalyst Accelerator/Incubator Minority 000 0000 000000 0
To view Tusk Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial